Clicky

Novo Nordisk A/S(NONOF) News

Date Title
Jun 20 Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Jun 20 Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Jun 20 Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
Jun 20 Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
Jun 20 How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
Jun 20 London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
Jun 20 Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Jun 20 Ricks Is the King of Pharma, Thanks to Lilly’s Zepbound
Jun 20 LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
Jun 20 Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Jun 19 What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
Jun 18 Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
Jun 18 Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
Jun 18 GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
Jun 18 Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
Jun 18 Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Jun 18 Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes
Jun 18 Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Jun 18 Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)
Jun 17 Trump's big beautiful bill: What the pharma industry is watching